Key Takeaways NVO reported positive data from a sub-analysis of its phase III REDEFINE 1 study on cagrilintide in obesity.Patients on cagrilintide lost 11.8% body weight compared to 2.3% with placebo after 68 weeks.Novo Nordisk plans to launch a dedicated phase III RENEW obesity program for cagrilintide in Q4 2025.Novo Nordisk (NVO) announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside li ...

盘前市场动向 1. 9月17日(周三)美股盘前，美股三大股指期货涨跌不一。截至发稿，道指期货涨0.07%，标普500指数期货跌0.04%，纳指期货 跌0.07%。 | = US 30 | 45,792.50 | 45,816.00 | 45,718.00 | +34.20 | +0.07% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,604.10 | 6.614.40 | 6,593.60 | -2.70 | -0.04% | | 트 US Tech 100 | 24,256.90 | 24,303.80 | 24,207.80 | -17.30 | -0.07% | 2. 截至发稿，德国DAX指数涨0.04%，英国富时100指数涨0.23%，法国CAC40指数跌0.24%，欧洲斯托克50指数跌0.10%。 | 德国DAX30 | 23,333.91 | 23,476.41 | 23,285.33 | +9.44 | +0.04% | | --- | --- | --- | --- | --- | --- | | 英国富时100 | 9,216 ...

华威大学临床副教授斯蒂芬.劳伦斯审阅数据后认为，超过10%的减重已足够产生显著临床效果，且研 究纳入多元化患者群体，反映了真实世界的用药场景。他强调："关键不在于减重多少，而在于这种形 式更易获得，口服制剂的易用性同样重要。" 在欧洲糖尿病研究协会会议上，医生们披露了礼来公司(LLY.US)减肥药Orforglipron片剂的大型临床试验 成果——该药物在肥胖成年患者中实现11.2%的显著减重效果，且副作用与当前注射剂类产品相当。礼 来计划在会议期间公布该药片主要肥胖试验的全部数据，并同步发表于《新英格兰医学杂志》。 尽管在另一项研究中，Orforglipron的减重效果略逊于礼来自家的注射药Zepbound及诺和诺德(NVO.US) 的Wegovy，但医生强调其口服形式将极大扩展治疗可及性——相比注射剂，片剂更易生产、使用更便 捷，最终可能更具价格优势。 研究主要作者之一、多伦多沃顿医疗诊所医学主任肖恩.沃顿指出："这彻底改变了肥胖症治疗方式，我 们终于能为更多急需帮助的患者提供服务。" 两公司在药物特性上存在关键差异：诺和诺德的药物与注射剂中的司美格鲁肽成分相同，生产更复杂、 使用限制更多(如饮食时间要求 ...

Topline The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they correct “false or misleading claims” about some of their popular weight-loss products after President Donald Trump signed an order designed to clamp down on drug advertising.The letters were issued a week ago. (Photo by Sarah Silbiger/Getty Images)Getty ImagesKey FactsThe warning letters were sent to over ...

For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the Trump administration’s crackdown on pharmaceutical advertising.The Food and Drug Administration on Tuesday posted more than 100 letters to various drugmakers and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered around lower-cost versions of blockbuster ob ...

The U.S. FDA has issued separate warning letters to Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) regarding claims made about their obesity drugs in an Oprah Winfrey video special. The video, "An Oprah Special: Shame, Blame, and the Weight Loss Revolution," mentioned Lilly's Zepbound and ...

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. LLY, is false or misleading.The agency's review found that the video misbrands the drugs by underplaying serious health risks and omitting critical safety information.LLY shares are advancing steadily. Check the analyst’s take here.The video, a 42-minute program hosted by Oprah Winfrey, focused on weight-loss treatments and their growing popula ...

Key Takeaways Amgen is advancing MariTide in late-stage obesity studies with promising monthly dosing potential.Viking's VK2735 showed weight loss benefits but faced high dropout rates in its oral study.AMGN stock posts gains with rising estimates, while VKTX stock sinks with widening projected losses.Though Amgen (AMGN) and Viking Therapeutics (VKTX) do not currently market any obesity drugs, they are among the few biotechs that have shown immense potential in this space.Amgen boasts a strong presence in o ...

Novo Nordisk A/S NVO reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. LLY.Martin Holst Lange, chief scientific officer at Novo Nordisk, confirmed the company's intentions Tuesday during the European Association for the Study of Diabetes conference in Vienna. Although the company has not yet formally announced its plans, it is preparing to submit an application to th ...

Key Takeaways Novo Nordisk won EU approval to update Rybelsus' label with cardiovascular benefits.The SOUL study showed Rybelsus cut the risk of major cardiovascular events by 14% versus placebo.Rybelsus is now the only oral GLP-1 in the EU for T2D with a proven cardiovascular benefit.Novo Nordisk (NVO) has secured European approval to update the label of oral GLP-1 drug for type II diabetes (T2D), Rybelsus (oral semaglutide), to reflect cardiovascular benefits demonstrated in the phase IIIb SOUL study. The ...